TY - JOUR
T1 - Position paper for the organization of ECMO programs for cardiac failure in adults
AU - for The International ECMO Network (ECMONet) and The Extracorporeal Life Support Organization (ELSO)
AU - Abrams, Darryl
AU - Garan, A. Reshad
AU - Abdelbary, Akram
AU - Bacchetta, Matthew
AU - Bartlett, Robert H.
AU - Beck, James
AU - Belohlavek, Jan
AU - Chen, Yih Sharng
AU - Fan, Eddy
AU - Ferguson, Niall D.
AU - Fowles, Jo anne
AU - Fraser, John
AU - Gong, Michelle
AU - Hassan, Ibrahim F.
AU - Hodgson, Carol
AU - Hou, Xiaotong
AU - Hryniewicz, Katarzyna
AU - Ichiba, Shingo
AU - Jakobleff, William A.
AU - Lorusso, Roberto
AU - MacLaren, Graeme
AU - McGuinness, Shay
AU - Mueller, Thomas
AU - Park, Pauline K.
AU - Peek, Giles
AU - Pellegrino, Vin
AU - Price, Susanna
AU - Rosenzweig, Erika B.
AU - Sakamoto, Tetsuya
AU - Salazar, Leonardo
AU - Schmidt, Matthieu
AU - Slutsky, Arthur S.
AU - Spaulding, Christian
AU - Takayama, Hiroo
AU - Takeda, Koji
AU - Vuylsteke, Alain
AU - Combes, Alain
AU - Brodie, Daniel
N1 - Funding Information:
CH is supported by a Future Leader Fellowship from the National Heart Foundation of Australia (Award ID: 101168); funding source had no role in the writing of the manuscript or the decision to submit for publication. PKP receives funding support from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), Food and Drug Administration/Biomedical Advanced Research and Development Authority (FDA/BARDA), Bristol-Myers Squibb, and AtoxBio; funding sources had no role in the writing of the manuscript or the decision to submit for publication.
Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature and ESICM.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Extracorporeal membrane oxygenation (ECMO) has been used increasingly for both respiratory and cardiac failure in adult patients. Indications for ECMO use in cardiac failure include severe refractory cardiogenic shock, refractory ventricular arrhythmia, active cardiopulmonary resuscitation for cardiac arrest, and acute or decompensated right heart failure. Evidence is emerging to guide the use of this therapy for some of these indications, but there remains a need for additional evidence to guide best practices. As a result, the use of ECMO may vary widely across centers. The purpose of this document is to highlight key aspects of care delivery, with the goal of codifying the current use of this rapidly growing technology. A major challenge in this field is the need to emergently deploy ECMO for cardiac failure, often with limited time to assess the appropriateness of patients for the intervention. For this reason, we advocate for a multidisciplinary team of experts to guide institutional use of this therapy and the care of patients receiving it. Rigorous patient selection and careful attention to potential complications are key factors in optimizing patient outcomes. Seamless patient transport and clearly defined pathways for transition of care to centers capable of providing heart replacement therapies (e.g., durable ventricular assist device or heart transplantation) are essential to providing the highest level of care for those patients stabilized by ECMO but unable to be weaned from the device. Ultimately, concentration of the most complex care at high-volume centers with advanced cardiac capabilities may be a way to significantly improve the care of this patient population.
AB - Extracorporeal membrane oxygenation (ECMO) has been used increasingly for both respiratory and cardiac failure in adult patients. Indications for ECMO use in cardiac failure include severe refractory cardiogenic shock, refractory ventricular arrhythmia, active cardiopulmonary resuscitation for cardiac arrest, and acute or decompensated right heart failure. Evidence is emerging to guide the use of this therapy for some of these indications, but there remains a need for additional evidence to guide best practices. As a result, the use of ECMO may vary widely across centers. The purpose of this document is to highlight key aspects of care delivery, with the goal of codifying the current use of this rapidly growing technology. A major challenge in this field is the need to emergently deploy ECMO for cardiac failure, often with limited time to assess the appropriateness of patients for the intervention. For this reason, we advocate for a multidisciplinary team of experts to guide institutional use of this therapy and the care of patients receiving it. Rigorous patient selection and careful attention to potential complications are key factors in optimizing patient outcomes. Seamless patient transport and clearly defined pathways for transition of care to centers capable of providing heart replacement therapies (e.g., durable ventricular assist device or heart transplantation) are essential to providing the highest level of care for those patients stabilized by ECMO but unable to be weaned from the device. Ultimately, concentration of the most complex care at high-volume centers with advanced cardiac capabilities may be a way to significantly improve the care of this patient population.
KW - Cardiac arrest
KW - Cardiac failure
KW - Critical care networks
KW - Extracorporeal life support
KW - Extracorporeal membrane oxygenation
KW - Hospital organization
KW - Mechanical circulatory support
KW - Position article
UR - http://www.scopus.com/inward/record.url?scp=85042090080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042090080&partnerID=8YFLogxK
U2 - 10.1007/s00134-018-5064-5
DO - 10.1007/s00134-018-5064-5
M3 - Article
C2 - 29450594
AN - SCOPUS:85042090080
SN - 0342-4642
VL - 44
SP - 717
EP - 729
JO - Intensive Care Medicine
JF - Intensive Care Medicine
IS - 6
ER -